← Browse by Condition
Medical Condition

autoimmune encephalitis

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for autoimmune encephalitis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — autoimmune encephalitis Clinical Trials

How many clinical trials are currently recruiting for autoimmune encephalitis?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for autoimmune encephalitis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for autoimmune encephalitis?
autoimmune encephalitis research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a autoimmune encephalitis clinical trial?
Eligibility criteria for autoimmune encephalitis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
University of Milano Bicocca 1 trial
Assistance Publique - Hôpitaux de Paris 1 trial
University of Utah 1 trial
Tongji Hospital 1 trial

Recruiting Clinical Trials

NCT06019975
Recruiting
FDG-PET in the Diagnosis of Autoimmune Encephalitis
Enrollment
90 pts
Location
Italy
Sponsor
University of Milano Bicocca
View Trial →
NCT06079294
Recruiting
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
Enrollment
56 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT04372615 Phase 2
Recruiting
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Enrollment
116 pts
Location
United States, Nethe...
Sponsor
University of Utah
View Trial →
NCT06584045
Recruiting
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)
Enrollment
250 pts
Location
China
Sponsor
Tongji Hospital
View Trial →

Related Conditions

encephalitis (2) encephalitis viral (1) autoimmune encephalitis caused by n methyl d aspartate receptor antibody (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology